We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Hikma Pharmaceuticals plc (PK) | USOTC:HKMPY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 50.39 | 47.77 | 52.84 | 64 | 21:00:16 |
From Jun 2019 to Jun 2024
By Carlo Martuscelli
Hikma Pharmaceuticals PLC (HIK.LN) will joint the FTSE 100 index, replacing Shire PLC (SHP.LN), FTSE Russell said Wednesday.
FTSE Russell attributed the swap to Shire's takeover by Takeda Pharmaceutical. London-listed Hikma Pharmaceuticals was founded in Jordan, and manufactures generic medicines as well as in-licensed products.
Shares of the company are up 65% in the past 12 months. Demand of its injectable medicines was recently buoyed by a shortage in the U.S., and the company reported earnings that beat analyst expectations in its latest half-year report.
FTSE Russell said that changes to the index will be made effective from Dec. 24.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
December 19, 2018 14:10 ET (19:10 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Hikma Pharmaceuticals (PK) Chart |
1 Month Hikma Pharmaceuticals (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
